New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Sanofi

SNY

Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.

Revenue
+13.9%
EPS
+8.21%
Free cash flow
+99.6%
Total debt
−11.2%

Quarter to September 2026, against a year earlier

46.62 0.56 +1.22%
Market cap
$111.3B
P/E
22.8×
Fwd P/E FY26e
—
Dividend yield
5.25%
F-score
7/9
ROIC
7.05%
Net debt / EBITDA
0.8×
Payout ratio
1.2×

Latest quarter Q3 FY2026 · quarter to September 2026

Revenue growth has slowed three quarters running, from 75.6% to 13.9%.

Q3 FY2026 and the seven quarters before it
Quarter Revenue, $m Growth, % Op. margin, % EPS, $
Q3 FY26 17,533 13.9 28.5 1.45
Q2 FY26 14,301 17.4 17.5 0.17
Q1 FY26 13,160 17.8 18.6 0.78
Q4 FY25 14,100 75.6 8.0 (0.38)
Q3 FY25 15,394 (1.1) 28.1 1.34
Q2 FY25 12,186 (0.6) 15.9 1.84
Q1 FY25 11,173 (7.4) 21.9 0.80
Q4 FY24 8,029 (38.9) 13.1 0.19

Against the consensus: revenue beat by 9.15% ($16.6B v $15.2B); adjusted EPS beat by $0.41 ($2.04 v $1.63).

Growth is on the same quarter a year earlier, and EPS is diluted. Negative figures in brackets.

Reports Feb 4, 2027 · Dec 2026 · consensus EPS $0.94

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 111,260
Revenue ttm 59,095
Net income ttm 4,506
Free cash flow ttm 23,793
Net debt Q 13,784
Valuation
P/E 22.8
Forward P/E FY26e —
Price / sales 1.9
Forward P/S FY26e Powerpack
Price / FCF 6.6
Price / book 1.4
Financial health
Current ratio Q 1.1
Debt / equity Q 0.2 (at or below 0.5: strong)
Interest coverage Q 19.6
Growth
Revenue growth FY26e —
EPS growth FY26e +6.1%
EPS growth FY27e +6.8%
EPS growth, 5 yrs e +7.3%
Insiders
Owned by insiders 0.8%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales 3.16% 4.37% 3.39%
Cash Flow 2.83% 7.41% 3.12%
Earnings 6.38% (8.87%) 0.08%
Book Value 2.30% 2.38% 0.82%

Valuation

P/E against its own 10 years 80.27%
10-year low 10-year high
P/S against its own 10 years 13.23%
10-year low 10-year high
P/B against its own 10 years 6.32%
10-year low 10-year high
EV/Sales against its own 10 years 11.14%
10-year low 10-year high
EV/FCF against its own 10 years 45.05%
10-year low 10-year high

Dividends raised 3 years running

Yield
5.25%
Annual rate
2.42
Payout ratio
119.8%
Growth, 2018–26
+3.83%/yr
  1. 1.79 ’18
  2. 1.72 ’19 −4
  3. 1.70 ’20 −1
  4. 1.93 ’21 +13
  5. 1.92 ’22 +0
  6. 1.90 ’23 −1
  7. 2.04 ’24 +7
  8. 2.20 ’25 +8
  9. 2.42 ’26 +10
paid change on the year, %

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1.9
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 38,408 40,921 42,135 42,147 42,687 46,348 47,822 50,266 47,922 52,854 59,095 +3.6% — — — —
Gross margin, % 69.17 67.93 67.95 68.18 67.47 68.72 69.83 69.35 70.18 72.07 73.44 +2.9 pt
EBT 6,283 6,251 5,202 3,161 15,768 9,226 10,981 7,742 7,248 6,986 7,151 +1.2%
EBT margin, % 16.36 15.27 12.35 7.50 36.94 19.91 22.96 15.40 15.12 13.22 12.10 (3.1) pt
Net income 5,211 9,533 5,085 3,143 14,066 7,362 8,820 5,844 5,947 5,588 4,506 +0.8%
Per share, $
Per share, $ Revenue 14.93 16.28 16.89 16.86 17.03 18.50 19.10 20.08 19.15 21.65 24.62 +4.2%
Earnings 2.03 1.76 2.04 1.24 5.61 2.94 3.52 2.33 2.48 3.62 2.02 +6.6%
Cash flow 3.37 3.32 2.63 3.47 3.39 4.97 4.43 4.43 3.93 4.98 9.91 +4.4%
Capex (0.81) (0.64) 0.09 (0.27) (0.54) (0.63) (0.30) (0.87) (0.75) (1.25) 0.00 +5.0%
Free cash flow 2.56 2.68 2.71 3.20 2.85 4.34 4.13 3.57 3.18 3.74 9.91 +4.3%
Book value 24.82 26.20 27.95 26.48 28.77 32.60 31.62 32.15 33.66 33.24 35.13 +3.3%
Shares, m 2,573 2,514 2,494 2,500 2,507 2,505 2,504 2,503 2,503 2,441 2,411 (0.6%)
Valuation, ×
Valuation, × P/E 20.11 24.17 12.01 12.95 3.74 6.59 13.80 21.19 20.08 13.46 22.80 14.8
P/S 2.75 2.66 2.06 2.04 1.91 1.87 2.57 2.49 2.52 2.24 1.87 2.3
P/B 1.65 1.65 1.61 1.90 1.58 1.62 1.55 1.56 1.43 1.46 1.37 1.6
EV/Sales 2.99 2.81 2.44 2.33 2.10 2.08 2.70 2.66 2.71 2.47 2.10 2.5
EV/FCF 8.24 6.69 6.84 8.39 8.80 7.52 5.01 5.16 6.33 7.02 7.43 7.0
Cash, $m
Cash, $m Operating cash flow 8,674 8,340 6,551 8,673 8,509 12,449 11,090 11,102 9,827 12,163 23,793 +3.8%
Capex (2,074) (1,606) 220 (663) (1,366) (1,568) (751) (2,174) (1,876) (3,045) (7,054) +4.4%
Free cash flow 6,600 6,734 6,771 8,010 7,143 10,881 10,339 8,928 7,950 9,118 23,793 +3.7%
Balance, $m
Balance, $m Working capital 11,346 12,315 8,507 9,218 16,512 10,966 10,601 7,009 14,528 2,950 3,959 (13.9%)
Net debt 9,191 5,975 20,921 17,089 9,820 12,077 6,632 8,314 9,262 12,370 13,784 +3.4%
Shareholders’ equity 63,877 65,849 69,720 66,201 72,133 81,671 79,180 80,472 84,249 81,133 84,300 +2.7%
Returns, %
Returns, % ROA 4.54 8.34 4.16 2.44 10.94 5.39 6.40 4.32 4.29 6.16 3.24 +1.6 pt
ROIC 6.49 6.15 4.30 5.46 12.50 6.56 7.81 6.75 5.49 6.57 7.05 +0.1 pt
ROE 8.11 14.70 7.50 4.62 20.34 9.57 10.97 7.32 7.31 10.69 0.00 +2.6 pt
People
People Employees 106,859 106,566 104,226 100,409 99,412 95,442 91,573 86,088 82,878 74,846 — (3.9%)
Revenue/emp, $m 0.36 0.38 0.40 0.42 0.43 0.49 0.52 0.58 0.58 0.71 — +7.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 5, 2026

Sanofi vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NVS Novartis AG $277.7B 28.8× 24.0× FY26e +4.67% (above 0%: growing) −68.81% (below 0%: shrinking) −17.81% (below 0%: shrinking) 75.99% 12.26% Compare
AZN AstraZeneca PLC $272.1B 24.6× 24.2× FY26e +6.70% (above 0%: growing) +23.46% (above 0%: growing) +1.99% (above 0%: growing) 81.82% 27.07% Compare
AMGN Amgen Inc. $237.4B 25.2× 24.0× FY26e +8.45% (above 0%: growing) +19.39% (above 0%: growing) −13.98% (below 0%: shrinking) 73.10% 35.79% Compare
GILD Gilead Sciences, Inc. $207.8B — (loss-making) — (loss-making) +6.83% (above 0%: growing) −20.16% (below 0%: shrinking) +21.13% (above 0%: growing) 81.07% 41.71% Compare
PFE Pfizer Inc. $158.2B 38.8× 18.7× FY26e −0.43% (below 0%: shrinking) −9.68% (below 0%: shrinking) +20.02% (above 0%: growing) 75.71% 22.14% Compare
NVO Novo Nordisk A/S $128.6B 9.8× — +3.87% (above 0%: growing) −17.14% (below 0%: shrinking) −14.75% (below 0%: shrinking) 76.97% 29.06% Compare
BMY Bristol Myers Squibb Company $119.3B 12.9× 12.0× FY26e +6.93% (above 0%: growing) −2.78% (below 0%: shrinking) −35.95% (below 0%: shrinking) 68.28% 19.40% Compare
SNY Sanofi $111.3B 22.8× — +13.89% (above 0%: growing) +8.21% (above 0%: growing) +99.60% (above 0%: growing) 76.16% 28.53%
GSK GSK PLC Sponsored ADR $95.9B 16.4× 15.5× FY26e +3.75% (above 0%: growing) −23.88% (below 0%: shrinking) +62.44% (above 0%: growing) 73.11% 23.93% Compare
Median of peers $183.0B 24.6× 21.4× +5.69% −13.41% −5.99% 75.85% 25.50%

All 21 Drug Manufacturers General stocks →

Sanofi (SNY) Latest News

What happened

  1. Deal Sanofi reportedly considered acquiring Insmed, a drugmaker valued at about $26.6 billion, but discussions were preliminary and no deal was assured.
  2. Product The FDA approved Sanofi's Infilbray for neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15 kg.
  3. Product The European Commission approved Sanofi's VaxRabeo for rabies prevention before and after exposure across all ages.
  4. Deal Sanofi signed a multi-target research and exclusive licensing deal with Seawolf worth up to $1.2 billion in milestone payments, plus tiered royalties.
9 more headlines
All SNY news, as stories →

SNY metrics, ten years each

stockrow.com/SNY · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com